Clearside Biomedical Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Clearside Biomedical de winst en omzet met respectievelijk 5.1% en 64.9% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 26.8% per jaar.

Belangrijke informatie

5.1%

Groei van de winst

26.8%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.9%
Inkomstengroei	64.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16

Winst- en omzetgroeiprognoses

NasdaqGM:CLSD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	11	-57	-54	N/A	5
12/31/2025	3	-46	-38	N/A	7
12/31/2024	2	-36	-8	N/A	6
9/30/2024	8	-32	-20	-19	N/A
6/30/2024	8	-33	-20	-19	N/A
3/31/2024	8	-35	-20	-19	N/A
12/31/2023	8	-32	-20	-18	N/A
9/30/2023	2	-37	-26	-24	N/A
6/30/2023	2	-36	-26	-24	N/A
3/31/2023	1	-35	-25	-24	N/A
12/31/2022	1	-33	-14	-13	N/A
9/30/2022	27	-5	-3	-3	N/A
6/30/2022	29	-2	0	0	N/A
3/31/2022	30	0	-1	-1	N/A
12/31/2021	30	0	-11	-11	N/A
9/30/2021	4	-25	-20	-20	N/A
6/30/2021	4	-23	-20	-20	N/A
3/31/2021	4	-23	-16	-16	N/A
12/31/2020	8	-18	-13	-13	N/A
9/30/2020	10	-14	-7	-7	N/A
6/30/2020	7	-18	-10	-10	N/A
3/31/2020	6	-18	-17	-17	N/A
12/31/2019	2	-31	-27	-27	N/A
9/30/2019	0	-49	-53	-53	N/A
6/30/2019	0	-67	-67	-67	N/A
3/31/2019	0	-82	-76	-76	N/A
12/31/2018	0	-83	-79	-79	N/A
9/30/2018	0	-78	-70	-70	N/A
6/30/2018	0	-72	N/A	-64	N/A
3/31/2018	0	-65	N/A	-56	N/A
12/31/2017	0	-59	N/A	-51	N/A
9/30/2017	0	-52	N/A	-42	N/A
6/30/2017	0	-39	N/A	-35	N/A
3/31/2017	0	-31	N/A	-29	N/A
12/31/2016	1	-26	N/A	-23	N/A
9/30/2016	1	-21	N/A	-20	N/A
6/30/2016	1	-19	N/A	-17	N/A
3/31/2016	1	-19	N/A	-15	N/A
12/31/2015	N/A	-18	N/A	-14	N/A
9/30/2015	N/A	-15	N/A	-13	N/A
6/30/2015	N/A	-15	N/A	-13	N/A
3/31/2015	N/A	-12	N/A	-11	N/A
12/31/2014	N/A	-10	N/A	-9	N/A
9/30/2014	N/A	-9	N/A	-8	N/A
6/30/2014	N/A	-8	N/A	-7	N/A
3/31/2014	N/A	-8	N/A	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CLSD de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CLSD de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CLSD de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CLSD ( 64.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CLSD ( 64.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CLSD naar verwachting over 3 jaar hoog zal zijn

Clearside Biomedical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 464%

Consensus revenue estimates increase by 362%

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

Price target decreased by 9.4% to US$5.80

Price target increased to US$7.50

Recent updates

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

High number of new directors

Clearside Biomedical: A Pivotal 2022 Ahead

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Price target decreased to US$10.40